CAH 8-K Current Reports
CARDINAL HEALTH INC - 370 current reports
CARDINAL HEALTH INC 8-K Report, Financial Results (Apr 30, 2026)
Cardinal Health, Inc. (CAH) has filed an 8-K report detailing its financial results for the third quarter ended March 31, 2026. The company announced its results via a press release filed as Exhibit 99.1, providing investors with key performance indicators and financial condition for the period. Management, including the CEO and CFO, will further discuss these results and provide an updated outlook for the fiscal year ending June 30, 2026, during a webcast scheduled for April 30, 2026. Investors should review the press release for detailed financial figures and management's commentary on operational performance. The webcast presentation and subsequent audio replay will offer additional insights into the company's strategic direction and future expectations. While specific financial figures are not detailed in the 8-K itself, these resources are expected to provide a comprehensive understanding of Cardinal Health's performance and outlook.
CARDINAL HEALTH INC 8-K Report, Executive Changes (Mar 23, 2026)
Cardinal Health, Inc. (CAH) has announced a significant leadership change via an 8-K filing. Gregory B. Kenny is retiring from his roles as a Director, committee member, and crucially, as Board Chair, effective March 20, 2026. Importantly, this retirement is not attributed to any disputes or disagreements regarding the company's operations or policies, suggesting a smooth transition. In light of this, the Board has appointed current director Patricia A. Hemingway Hall as the new Board Chair, effective immediately. Furthermore, alongside this leadership transition, Cardinal Health confirmed its third quarter fiscal 2026 earnings release date as April 30, 2026, and reiterated its confidence in its fiscal 2026 outlook. Investors should note the continuity in leadership philosophy and the reaffirmation of financial projections.
CARDINAL HEALTH INC 8-K Report, Executive Changes (Mar 5, 2026)
Cardinal Health, Inc. (CAH) has announced the upcoming retirement of its Senior Vice President and Chief Accounting Officer, Mary Scherer. Ms. Scherer has informed the company of her intention to retire in February 2027. This announcement triggers the initiation of a search process for a successor to ensure continuity in financial leadership. Investors should note that Ms. Scherer will remain in her role until her successor is fully onboarded, indicating a commitment to a well-managed transition. The company has not provided details on the search process or potential candidates at this time.
CARDINAL HEALTH INC 8-K Report, Financial Results (Feb 5, 2026)
Cardinal Health, Inc. (CAH) has filed a Form 8-K on February 5, 2026, to report its financial results for the second quarter ended December 31, 2025. The filing primarily references a press release (Exhibit 99.1) containing these results, making the detailed financial performance available to investors. The company also announced an upcoming webcast to discuss these quarterly results and provide an updated outlook for the fiscal year ending June 30, 2026, with management commentary from the CEO and CFO. The presentation materials for this webcast will be accessible on the company's investor relations website.
CARDINAL HEALTH INC 8-K Report, Regulation FD Disclosure (Jan 13, 2026)
Cardinal Health, Inc. (CAH) has filed a Form 8-K on January 13, 2026, primarily to provide an update to its previously issued fiscal year 2026 non-GAAP earnings per share (EPS) outlook. While the specific details of the updated outlook are not included in the 8-K itself, the filing indicates that this information was disclosed in a press release issued on the same date. Investors should note that Cardinal Health will also be participating in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. This conference appearance often serves as a platform for management to provide further color on business performance, strategic initiatives, and financial guidance. The press release, attached as an exhibit, is the primary source for the updated EPS outlook and any other material information shared.
CARDINAL HEALTH INC 8-K Report, Shareholder Vote Results (Nov 6, 2025)
Cardinal Health, Inc. (CAH) has filed an 8-K reporting the results of its 2025 Annual Meeting of Shareholders, held on November 5, 2025. The meeting primarily focused on shareholder votes concerning the Board of Directors, executive compensation, and the ratification of the independent auditor. All 12 director nominees were overwhelmingly elected, indicating strong shareholder confidence in the current board's leadership and strategic direction. The company also received a positive advisory vote on executive compensation, reflecting shareholder approval of the compensation packages for its named executive officers. Furthermore, shareholders ratified the appointment of Ernst & Young LLP as the independent auditor for the upcoming fiscal year. This outcome suggests a stable governance environment and continued support for the company's financial oversight. Investors should view these results as indicators of continued operational and strategic stability within Cardinal Health.
CARDINAL HEALTH INC 8-K Report, Financial Results (Oct 30, 2025)
Cardinal Health, Inc. (CAH) has filed an 8-K report on October 29, 2025, detailing its financial results for the quarter ended September 30, 2025. The company issued a press release on October 30, 2025, to announce these results, which is included as an exhibit to this filing. This report serves as the primary source for investors to understand the company's recent performance. Furthermore, Cardinal Health is scheduled to hold a webcast on October 30, 2025, where its CEO and CFO will discuss the first-quarter results and provide an outlook for the fiscal year ending June 30, 2026. The accompanying presentation slides and an audio replay of the webcast will be made available on the company's investor relations website, offering additional insights and context for shareholders and potential investors.
CARDINAL HEALTH INC 8-K Report, Material Agreement (Oct 10, 2025)
Cardinal Health, Inc. (CAH) has entered into a new 364-Day Credit Agreement, effective October 7, 2025, replacing its prior agreement. This new facility provides the company with access to $1.0 billion in revolving credit, extending through October 6, 2026. This ensures continued financial flexibility for general corporate purposes and supports its commercial paper program. A key feature allows for the potential conversion of outstanding loans into non-revolving term loans, payable one year after the agreement's termination date, offering further flexibility in managing its debt obligations.
CARDINAL HEALTH INC 8-K Report, Material Agreement (Oct 3, 2025)
Cardinal Health Inc. (CAH) has filed an 8-K report detailing a significant amendment to its receivables financing agreement. On September 30, 2025, Cardinal Health Funding, LLC, along with its subsidiaries and various financial institutions including Wells Fargo Bank, N.A., Liberty Street Funding LLC, The Bank of Nova Scotia, PNC Bank, National Association, Bank of America, National Association, Victory Receivables Corporation, and MUFG Bank, LTD, entered into a First Amendment to their Fifth Amended and Restated Receivables Purchase Agreement, originally dated September 1, 2023. The primary objective and impact of this amendment is to extend the maturity date of the existing receivables financing facility. The agreement's term has been successfully extended to September 28, 2028. This extension provides continued access to a crucial source of funding for the company's operations, offering financial stability and flexibility over the next three years. Investors can view the full details of this amendment as Exhibit 10.1 to the filing.
CARDINAL HEALTH INC 8-K Report, Material Agreement (Aug 27, 2025)
Cardinal Health, Inc. (CAH) has announced the completion of a significant public offering, raising a total of $1.0 billion through the issuance of new debt. This includes $600 million in 4.500% Notes due 2030 and $400 million in 5.150% Notes due 2035. The primary purpose of this debt issuance is to fund a portion of the consideration and associated expenses for its proposed acquisition of Solaris Health. This strategic move indicates Cardinal Health's commitment to expanding its operations through acquisition. Investors should note the terms associated with this debt. The proceeds are not held in escrow and are available for general corporate purposes pending the closing of the Solaris Health acquisition. However, a critical contingency exists: if the acquisition does not close by August 12, 2026, or if Cardinal Health decides not to proceed with it, the company is obligated to redeem all issued Notes at a premium (101% of principal plus accrued interest). This special mandatory redemption provision acts as a safeguard for noteholders, ensuring their investment is protected in the event the acquisition fails to materialize.
CARDINAL HEALTH INC 8-K Report, Corporate Update (Aug 14, 2025)
Cardinal Health, Inc. (CAH) announced on August 13, 2025, that it has entered into an underwriting agreement to issue and sell a significant amount of senior notes. This offering comprises $600 million in 4.500% Notes due 2030 and $400 million in 5.150% Notes due 2035, totaling $1 billion in aggregate principal. The issuance is being conducted under a previously effective registration statement filed with the SEC. This debt financing represents a strategic move by Cardinal Health to potentially fund its operations, investments, or refinance existing debt. Investors should note the coupon rates and maturity dates of these new notes, which provide insights into the company's cost of capital and its long-term financial strategy. The aggregate size of the offering indicates a substantial capital raise, and the specific terms will be detailed in the filed underwriting agreement.
CARDINAL HEALTH INC 8-K Report, Financial Results (Aug 12, 2025)
Cardinal Health, Inc. (CAH) has filed an 8-K report detailing its financial results for the fourth quarter and full fiscal year ended June 30, 2025. The company announced these results via a press release on August 12, 2025, which is attached as an exhibit. Investors can expect a deeper dive into these results and the company's outlook for the upcoming fiscal year ending June 30, 2026, during an investor webcast scheduled for August 12, 2025, featuring the CEO and CFO. The accompanying slide presentation and audio replay will be available on the company's investor relations website. In addition to the financial results, the 8-K also discloses a significant strategic move: Cardinal Health's multi-specialty MSO, The Specialty Alliance, has entered into a definitive agreement to acquire Solaris Health. This acquisition, also announced via press release, represents a notable development for the company's business operations and future growth strategy, and further details are expected to be discussed during the webcast.
CARDINAL HEALTH INC 8-K Report, Regulation FD Disclosure (Jun 12, 2025)
Cardinal Health, Inc. (CAH) has filed an 8-K report detailing significant updates presented at their Investor Day on June 12, 2025. The company announced its revised fiscal year 2025 outlook, alongside a preliminary outlook for fiscal year 2026. This forward-looking guidance is crucial for investors seeking to understand the company's near-term performance expectations and its strategic direction over the next 18-24 months. In addition to financial projections, Cardinal Health also provided updates on its long-term financial targets and strategic initiatives. These broader updates are designed to provide a clearer picture of the company's growth strategy, operational improvements, and capital allocation priorities. Investors should pay close attention to these strategic disclosures as they may indicate potential shifts in business focus or investment in key growth areas. The Investor Day webcast and presentation are available on the company's Investor Relations website for detailed review.
CARDINAL HEALTH INC 8-K Report, Financial Results (May 1, 2025)
Cardinal Health, Inc. (CAH) has filed an 8-K report on May 1, 2025, disclosing its financial results for the third quarter ended March 31, 2025. The report primarily serves to announce the release of their earnings via a press release, which is attached as an exhibit. Investors should note that the detailed financial performance, including revenue, profitability, and any significant variances, will be found within the referenced news release (Exhibit 99.1).
CARDINAL HEALTH INC 8-K Report, Executive Changes (Mar 10, 2025)
Cardinal Health, Inc. (CAH) announced a significant expansion of its Board of Directors with the immediate election of two new independent directors, Robert W. Musslewhite and Sudhakar Ramakrishna, effective March 7, 2025. Both individuals bring extensive leadership experience from the technology and healthcare sectors. Mr. Musslewhite, former CEO of Definitive Healthcare Corp., and Mr. Ramakrishna, CEO of SolarWinds Corporation, have been appointed to key board committees, including Audit, Human Resources and Compensation, and Risk Oversight. Their appointments are expected to enhance the board's expertise and strategic oversight.
CARDINAL HEALTH INC 8-K Report, Financial Results (Jan 30, 2025)
Cardinal Health, Inc. (CAH) filed an 8-K on January 30, 2025, to announce its financial results for the second quarter ended December 31, 2024. The core of this filing revolves around the accompanying news release, which contains the detailed financial performance and operational updates for the period. Investors should refer to this news release, attached as Exhibit 99.1, for the specific figures and commentary regarding revenue, profitability, and any significant business developments. Furthermore, the company has scheduled a webcast for January 30, 2025, where the CEO and CFO will provide further insights into the quarter's performance and discuss the outlook for the fiscal year ending June 30, 2025. This event, along with the slide presentation and audio replay, will be accessible through the company's investor relations website, offering a platform for deeper understanding of management's perspective on the current financial standing and future guidance.
CARDINAL HEALTH INC 8-K Report, Regulation FD Disclosure (Jan 14, 2025)
Cardinal Health Inc. (CAH) has announced an upward revision to its fiscal year 2025 non-GAAP diluted earnings per share (EPS) guidance. The company now expects its non-GAAP EPS to be toward the high end of its previously stated range of $7.75 to $7.90. This positive adjustment is primarily attributed to the sustained strong performance within its Pharmaceutical and Specialty Solutions segment. Investors should note that the company will be presenting at the JP Morgan 43rd Annual Healthcare Conference on January 14, 2025, where further commentary on this update is expected. Additionally, more comprehensive details regarding fiscal year 2025 expectations will be provided during the second quarter earnings call scheduled for January 30, 2025. The company emphasizes that it does not provide forward-looking guidance on a GAAP basis due to the unavailability of certain significant financial information.
CARDINAL HEALTH INC 8-K Report, Material Agreement (Dec 9, 2024)
Cardinal Health, Inc. (CAH) has entered into a new $1.0 billion Term Loan Credit Agreement with Bank of America, N.A., as Administrative Agent. This new facility is designed to provide funding for the cash consideration and related expenses associated with its previously announced acquisitions of The GI Alliance Holdings, LLC and Advanced Diabetes Supply Group. The credit agreement is set to terminate on November 10, 2025, unless certain conditions related to the consummation of these acquisitions are met earlier. Once drawn, the loans will mature three years after the borrowing date, subject to acceleration under specific circumstances.
CARDINAL HEALTH INC 8-K Report, Material Agreement (Nov 22, 2024)
Cardinal Health, Inc. (CAH) has filed an 8-K report detailing a significant debt financing event. The company successfully completed a public offering, raising a total of $2.85 billion through the issuance of four tranches of senior notes with varying maturity dates and interest rates. These notes include $500 million in 4.700% Notes due 2026, $750 million in 5.000% Notes due 2029, $1 billion in 5.350% Notes due 2034, and $650 million in 5.750% Notes due 2054. The primary purpose of this debt issuance is to fund a portion of the consideration for two anticipated acquisitions: The GI Alliance Holdings, LLC (GIA Acquisition) and Advanced Diabetes Supply Group. This strategic move signals Cardinal Health's intent to expand its operations through targeted acquisitions. The company also disclosed that if the GIA Acquisition is not consummated by a specified date, or if the company decides not to proceed, it will be required to redeem these notes at a premium (101% of principal plus accrued interest), indicating a contingency plan tied to the success of the GIA Acquisition.
CARDINAL HEALTH INC 8-K Report, Corporate Update (Nov 18, 2024)
Cardinal Health, Inc. (CAH) announced on November 17, 2024, its entry into an underwriting agreement to issue a substantial amount of senior notes across various maturities. This debt offering, totaling $2.9 billion, includes notes due in 2026, 2029, 2034, and 2054 with coupon rates ranging from 4.700% to 5.750%. This move indicates the company is actively managing its capital structure and likely seeking to refinance existing debt, fund ongoing operations, or support strategic initiatives. Investors should note the significant increase in leverage this offering represents and evaluate the company's ability to service this new debt, considering its current financial health and future cash flow generation. The issuance was made under a previously effective registration statement, suggesting a well-planned financing strategy.
CARDINAL HEALTH INC 8-K Report, Material Agreement (Nov 12, 2024)
Cardinal Health, Inc. (CAH) has announced a significant strategic move with the entry into an Agreement and Plan of Merger to acquire approximately 71% of The GI Alliance Holdings, LLC (GIA) for approximately $2.8 billion. This acquisition, expected to close subject to regulatory approval and customary conditions, marks a substantial investment aimed at expanding Cardinal Health's presence in the gastroenterology market. The company has secured committed financing for the transaction through a $2.9 billion senior unsecured bridge term loan facility from Bank of America, N.A. This provides flexibility for the acquisition and related expenses. Additionally, Cardinal Health has included a call option in the merger agreement to acquire the remaining outstanding equity of GIA in the future, signaling a long-term commitment to this strategic venture.
CARDINAL HEALTH INC 8-K Report, Shareholder Vote Results (Nov 7, 2024)
Cardinal Health, Inc. (CAH) filed an 8-K report detailing the results of its 2024 Annual Meeting of Shareholders, held on November 6, 2024. The primary focus of the filing is the outcome of four key proposals voted upon by shareholders. Notably, all ten director nominees were elected to the board, indicating strong shareholder confidence in the current leadership and governance structure. Shareholders also approved, on a non-binding advisory basis, the compensation of the company's named executive officers, often referred to as the 'say-on-pay' vote, with a majority in favor. The ratification of Ernst & Young LLP as the independent auditor for the upcoming fiscal year also received overwhelming support. However, a shareholder proposal aimed at prohibiting the re-nomination of directors who fail to receive a majority vote was not approved, suggesting a preference among shareholders for the current director nomination and election process. Overall, the filing shows positive shareholder sentiment towards board composition, executive compensation, and auditor selection, while indicating a rejection of a specific governance change proposal.
CARDINAL HEALTH INC 8-K Report, Financial Results (Nov 1, 2024)
Cardinal Health, Inc. (CAH) has filed a Form 8-K to report its financial results for the first quarter ended September 30, 2024. The primary purpose of this filing is to disseminate information regarding the company's performance, which was announced via a press release included as an exhibit. Investors should refer to this press release for detailed financial figures and operational commentary.
CARDINAL HEALTH INC 8-K Report, Material Agreement (Oct 10, 2024)
Cardinal Health Inc. (CAH) has entered into a new 364-Day Credit Agreement, securing access to a $1.0 billion revolving credit facility maturing on October 7, 2025. This facility is intended for general corporate purposes and will back the company's commercial paper program. The agreement includes standard covenants, with a key financial covenant requiring a Consolidated Net Leverage Ratio of no greater than 3.75 to 1.00. Additionally, the company has amended its Issuing and Paying Agency Agreement to increase the maximum principal amount of commercial paper notes outstanding from $2.0 billion to $3.0 billion. These actions indicate a proactive approach to managing liquidity and financing needs.
CARDINAL HEALTH INC 8-K Report, Executive Changes (Sep 9, 2024)
Cardinal Health, Inc. (CAH) filed an 8-K report announcing the decision of two Board of Directors members, Steven K. Barg and Sujatha Chandrasekaran, not to stand for re-election at the upcoming 2024 annual shareholder meeting. Both directors, who joined the board in 2022 as part of a cooperation agreement with Elliott Associates, will continue their service until the meeting concludes. Their departure is stated to be unrelated to any disagreements with the company's operations or policies. Mr. Barg served on the now-sunsetted Business Review Committee and currently sits on the Governance and Sustainability Committee, while Ms. Chandrasekaran is a member of the Audit and Risk Oversight Committees. The company expressed gratitude for their contributions during their tenure.
CARDINAL HEALTH INC 8-K Report, Financial Results (Aug 14, 2024)
Cardinal Health, Inc. (CAH) has filed an 8-K report on August 14, 2024, detailing its financial results for the fourth quarter and full fiscal year ended June 30, 2024. The primary driver of this filing is the press release (Exhibit 99.1) announcing these results, which provides investors with the latest performance figures. The company also announced that its CEO and CFO will discuss these results, along with the outlook for the fiscal year ending June 30, 2025, during a webcast scheduled for August 14, 2024. The presentation slides and an audio replay of the webcast will be made available on the company's investor relations website.
CARDINAL HEALTH INC 8-K Report, Financial Results (May 2, 2024)
Cardinal Health, Inc. (CAH) filed an 8-K on May 2, 2024, primarily to announce its financial results for the third quarter ended March 31, 2024. The filing references a press release (Exhibit 99.1) that contains the detailed financial performance for the quarter. Investors should refer to this press release for specific figures regarding revenue, earnings, and other key financial metrics. Furthermore, the report indicates that management will host a webcast on May 2, 2024, to discuss these results, provide an updated outlook for the full fiscal year ending June 30, 2024, and offer a preliminary outlook for the fiscal year ending June 30, 2025. The slide presentation and an audio replay of this webcast will be made available on the company's investor relations website, providing crucial forward-looking information and context for investors.
CARDINAL HEALTH INC 8-K Report, Regulation FD Disclosure (Apr 23, 2024)
Cardinal Health Inc. (CAH) has filed an 8-K report detailing a voluntary restructuring of its operating and reporting segments, effective from the third quarter of fiscal year 2024. This initiative aims to simplify the company's structure, enhance operational focus, and improve accountability and transparency. Investors should note that this filing provides unaudited, recast segment results for fiscal years 2022 and 2023, as well as the first two quarters of fiscal year 2024, under this new framework. The company has consolidated its reporting into two primary segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. Three smaller operating segments—Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight® Logistics—will be reported collectively under 'Other.' Importantly, these recast results do not alter previously reported consolidated financial figures like revenue, operating earnings, net earnings, or EPS. The changes primarily affect how inter-segment revenues and allocated corporate expenses are treated within the new reporting structure.
CARDINAL HEALTH INC 8-K Report, Regulation FD Disclosure (Apr 22, 2024)
Cardinal Health, Inc. (CAH) has filed an 8-K report on April 22, 2024, to disclose a significant business development: the non-renewal of its pharmaceutical distribution contracts with OptumRx. This announcement, made via a press release, signals a substantial shift in Cardinal Health's customer relationships and could have implications for its future revenue streams and market position within the pharmaceutical distribution segment. Investors should pay close attention to the potential impact of losing a major client like OptumRx. While the specifics of the non-renewal terms and the timeline are not detailed in this 8-K, the event warrants a closer look at Cardinal Health's customer concentration, its strategies for mitigating the financial impact, and its overall outlook for the pharmaceutical distribution business. This development could also influence investor sentiment and necessitate a review of the company's long-term growth prospects.
CARDINAL HEALTH INC 8-K Report, Executive Changes (Feb 28, 2024)
Cardinal Health, Inc. (CAH) announced a key board appointment in its recent 8-K filing. Robert W. Azelby has been elected to the Board of Directors, effective March 1, 2024. Mr. Azelby brings a background as the former President and Chief Executive Officer of Eliem Therapeutics, Inc., a biotechnology firm. His appointment is expected to enhance the Board's expertise, particularly with his inclusion on the Risk Oversight Committee. This appointment is effective until the upcoming 2024 annual shareholder meeting. The company confirmed that Mr. Azelby meets the independence requirements set by the NYSE and SEC. His compensation will align with that of other non-employee directors. This move suggests a continued focus on strengthening board governance and risk management as the company navigates its strategic objectives.
CARDINAL HEALTH INC 8-K Report, Material Agreement (Feb 20, 2024)
Cardinal Health, Inc. (CAH) has filed an 8-K report detailing a significant financing event. On February 20, 2024, the company successfully completed a public offering of new debt securities, raising a total of $1.15 billion. This offering consisted of $650 million in 5.125% Notes due in 2029 and $500 million in 5.450% Notes due in 2034. The issuance of these notes represents a material definitive agreement and the creation of a direct financial obligation for the company. The proceeds from this offering are expected to be used for general corporate purposes. This action signals the company's ongoing strategy to manage its capital structure and fund its operations.
CARDINAL HEALTH INC 8-K Report, Financial Results (Feb 1, 2024)
Cardinal Health, Inc. (CAH) has filed an 8-K report on February 1, 2024, primarily announcing its financial results for the second quarter ended December 31, 2023. The report includes a press release detailing these results, which are also being discussed by company leadership during a webcast on February 1, 2024. Investors should refer to the press release (Exhibit 99.1) for specific financial figures and operational performance details for the quarter. The company is also providing an outlook for the fiscal year ending June 30, 2024, during the aforementioned webcast. This forward-looking information is crucial for investors assessing the company's future performance and strategic direction. Both the webcast presentation slides and an audio replay will be made available on the company's investor relations website, ir.cardinalhealth.com, allowing investors to access these key updates.
CARDINAL HEALTH INC 8-K Report, Financial Results (Jan 9, 2024)
Cardinal Health, Inc. (CAH) has filed an 8-K report on January 9, 2024, to announce significant updates regarding its business and financial outlook. The company is providing an updated enterprise operating and segment reporting structure as part of an ongoing business and portfolio review. This structural change signals a strategic re-evaluation aimed at optimizing performance and potentially streamlining operations. Investors should pay close attention to how this new structure impacts future segment performance and overall company strategy. Furthermore, Cardinal Health has revised its fiscal year 2024 non-GAAP diluted earnings per share (EPS) outlook upwards. This upward revision suggests management's increased confidence in the company's ability to achieve its financial targets for the year. Additionally, the company provided an update on its Medical segment profit expectations for the quarter ending December 31, 2023, indicating potential strength or positive developments within this specific business unit. These announcements were made via a press release, and management is hosting a conference call to discuss these developments further.
CARDINAL HEALTH INC 8-K Report, Shareholder Vote Results (Nov 16, 2023)
Cardinal Health, Inc. (CAH) filed an 8-K on November 16, 2023, reporting the results of its Annual Meeting of Shareholders held on November 15, 2023. The primary focus of this filing is the outcome of six proposals voted upon by shareholders. Investors will be interested to note that all director nominees were elected, and the company's appointment of Ernst & Young LLP as its independent auditor for fiscal year 2024 was ratified with overwhelming support. Additionally, shareholders approved the executive compensation on an advisory basis (say-on-pay) and supported holding such votes annually. However, two shareholder proposals did not pass: one seeking a policy for executive stock retention and another for shareholder ratification of excessive termination pay. These outcomes suggest that while shareholders are generally aligned with the board's composition and compensation practices, they rejected specific proposals aimed at increasing executive accountability through stock retention and termination pay oversight. The high number of broker non-votes on most proposals indicates that a significant portion of shares held in 'street name' did not have voting instructions from the beneficial owners for these particular items.
CARDINAL HEALTH INC 8-K Report, Financial Results (Nov 3, 2023)
Cardinal Health, Inc. (CAH) filed an 8-K on November 3, 2023, to announce its financial results for the first quarter ended September 30, 2023. The company released its earnings through a press release, which is attached as an exhibit. This filing serves as a primary source for investors seeking the latest financial performance data and management's commentary on the company's trajectory. Investors can expect further details and forward-looking statements during a webcast scheduled for November 3, 2023, featuring the CEO and CFO. This webcast will cover the first-quarter results and provide an outlook for the fiscal year ending June 30, 2024. Presentation materials and an audio replay will be accessible on the company's investor relations website.
CARDINAL HEALTH INC 8-K Report, Material Agreement (Sep 6, 2023)
Cardinal Health Inc. (CAH) announced a significant amendment and restatement to its receivables purchase agreement on September 1, 2023. This strategic move involves adding a new subsidiary, Cardinal Health 23 Funding, LLC (CH-23 Funding), as an additional seller of receivables under its $1.0 billion committed receivables sales facility. Furthermore, the company has appointed another subsidiary, Cardinal Health 23, LLC (CH-23), as the new servicer for this facility, replacing Griffin Capital. These changes are expected to enhance the efficiency and structure of Cardinal Health's receivables financing operations. In conjunction with this amendment, the Company has also entered into a Performance Guaranty to back the obligations of its affiliated originators and CH-23 as the servicer. This guaranty includes compliance with certain financial covenants, indicating a commitment to the new servicing arrangement and the overall financial health of the program. Investors should view this as a procedural update aimed at optimizing the company's financing capabilities.
CARDINAL HEALTH INC 8-K Report, Financial Results (Aug 15, 2023)
Cardinal Health Inc. (CAH) filed an 8-K on August 14, 2023, detailing its financial results for the quarter and fiscal year ended June 30, 2023. The company announced these results via a press release filed as Exhibit 99.1. This report also disclosed the upcoming departure of a long-standing Board member, Carrie S. Cox, who will not seek re-election at the upcoming shareholder meeting, citing no disagreements with the company. Furthermore, the 8-K announced a webcast scheduled for August 15, 2023, where the CEO and CFO would discuss the recently reported financial performance and provide an outlook for the fiscal year ending June 30, 2024. Investors are encouraged to review the press release and the webcast presentation for detailed financial information and future guidance.
CARDINAL HEALTH INC 8-K Report, Regulation FD Disclosure (Jun 8, 2023)
Cardinal Health, Inc. (CAH) filed an 8-K on June 8, 2023, to announce significant updates regarding its financial outlook and strategic direction, as detailed in a press release furnished as an exhibit. The company provided an updated outlook for fiscal year 2023 and a preliminary outlook for fiscal year 2024. Investors should note the introduction of long-term financial targets and an updated capital allocation framework, which signal a renewed focus on shareholder value and disciplined financial management. These announcements were made in conjunction with an Investor Day event where management further elaborated on growth strategies and ongoing business reviews.
CARDINAL HEALTH INC 8-K Report, Bylaw Amendment (May 11, 2023)
Cardinal Health, Inc. (CAH) filed an 8-K on May 11, 2023, primarily to announce an amendment and restatement of its Code of Regulations, effective immediately. The core purpose of these amendments is to align the Company's procedures with the U.S. Securities and Exchange Commission's (SEC) new "universal proxy" rules (Rule 14a-19). This update is crucial for shareholders intending to nominate directors for consideration at the company's meetings.
CARDINAL HEALTH INC 8-K Report, Material Agreement (May 4, 2023)
Cardinal Health Inc. (CAH) filed an 8-K on May 4, 2023, primarily related to the extension of a cooperation agreement with Elliott Associates, L.P. and its affiliates. This amendment to the September 2022 agreement extends its term until at least July 15, 2024, and also extends the term of the Company's Business Review Committee. This suggests continued engagement and a potentially longer-term strategic dialogue between the Company and Elliott. The filing also serves as a notification of the Company's financial results for the quarter ended March 31, 2023, which were released via a press announcement on May 4, 2023. While the 8-K itself doesn't detail these results, it directs investors to the press release (Exhibit 99.1) and upcoming investor webcast scheduled for May 4, 2023, where management will discuss the quarterly performance and provide an updated outlook for the fiscal year ending June 30, 2023. Investors should review these related materials for specific financial performance details.
CARDINAL HEALTH INC 8-K Report, Material Agreement (Mar 2, 2023)
Cardinal Health, Inc. (CAH) filed an 8-K on March 1, 2023, detailing a significant update to its financing structure. The company entered into a Third Amended and Restated Five-Year Credit Agreement, which provides access to a $2.0 billion revolving credit facility and extends its term to February 25, 2028. This refinancing enhances the company's financial flexibility and liquidity. The agreement includes customary covenants, with a key financial covenant requiring a Consolidated Net Leverage Ratio of no greater than 3.75 to 1.00. Notably, the new credit agreement incorporates provisions for Environmental, Social, and Governance (ESG) targets, allowing for potential adjustments to facility fees and margins based on performance. This demonstrates Cardinal Health's commitment to integrating ESG considerations into its financing. The facility backs the company's commercial paper program and is available for general corporate purposes, underscoring its importance for ongoing operational needs.
CARDINAL HEALTH INC 8-K Report, Financial Results (Feb 2, 2023)
Cardinal Health, Inc. (CAH) filed an 8-K on February 2, 2023, to report its financial results for the second quarter ended December 31, 2022. The company issued a press release detailing these results, which is attached as an exhibit to this filing. Investors should note that the company's CEO and CFO will discuss these results and provide an outlook for the fiscal year ending June 30, 2023, during a webcast scheduled for February 2, 2023. While the specific financial figures are contained within the referenced press release (Exhibit 99.1), this 8-K serves as the official notification of the results announcement. Interested parties are directed to the press release for the detailed financial performance and to the company's investor relations website for the webcast presentation and audio replay. This filing primarily indicates the release of Q2 FY23 results and forward-looking guidance.
CARDINAL HEALTH INC 8-K Report, Executive Changes (Dec 19, 2022)
Cardinal Health, Inc. (CAH) announced a significant leadership change in its finance department via an 8-K filing on December 19, 2022. The company has appointed Aaron E. Alt as its new Chief Financial Officer (CFO), effective February 10, 2023. Mr. Alt brings a wealth of experience from his previous roles as CFO at Sysco Corporation and Sally Beauty Holdings, as well as senior operational and financial positions at Target Corporation. This appointment signals a move to strengthen the company's financial leadership with a seasoned executive from the distribution and retail sectors. Investors should note the comprehensive compensation package offered to Mr. Alt, designed to attract and retain top talent. This includes a substantial base salary, performance-based bonuses, long-term incentive awards, a significant sign-on bonus, and relocation assistance. The focus on performance-based incentives and the substantial equity awards suggest a alignment of management's interests with long-term shareholder value creation. Patricia M. English will continue to serve as interim CFO until Mr. Alt's official start date, ensuring a smooth transition.
CARDINAL HEALTH INC 8-K Report, Shareholder Vote Results (Nov 10, 2022)
Cardinal Health, Inc. (CAH) filed an 8-K on November 9, 2022, reporting the outcomes of its 2022 Annual Meeting of Shareholders held on November 9, 2022. The meeting focused on three key proposals, all of which received majority support from shareholders. This indicates a general approval of the company's board of directors, its choice of auditor, and its executive compensation structure as presented. For investors, the most significant takeaway is the shareholder ratification of the board nominees and the company's chosen independent auditor. The strong support for the executive compensation plan, despite being advisory, also signals shareholder confidence in the current management's remuneration policies. The high number of 'For' votes across all proposals, coupled with relatively low 'Against' and 'Abstained' votes, suggests stability and alignment between the company and its shareholder base regarding these critical governance matters.
CARDINAL HEALTH INC 8-K Report, Financial Results (Nov 4, 2022)
Cardinal Health, Inc. (CAH) filed an 8-K on November 4, 2022, to announce its financial results for the first quarter ended September 30, 2022. The report primarily serves as a notification that the company has released its earnings and will be holding a webcast to discuss these results and provide its fiscal year 2023 outlook. Investors should refer to the news release (Exhibit 99.1) and the upcoming webcast for detailed financial performance and forward-looking statements. While this 8-K filing itself does not contain the specific financial figures, it signals the availability of this crucial information. The company's management, including the CEO and CFO, will elaborate on the quarterly performance and offer guidance for the fiscal year ending June 30, 2023, during the scheduled webcast. The webcast presentation and subsequent audio replay will be accessible on the company's investor relations website.
CARDINAL HEALTH INC 8-K Report, Material Agreement (Oct 4, 2022)
Cardinal Health, Inc. (CAH) announced a significant amendment to its receivables financing facility. On September 30, 2022, the company, through its subsidiary Cardinal Health Funding, LLC, extended its $1.0 billion committed receivables sales facility program from September 30, 2022, to September 30, 2025. This extension provides continued access to crucial short-term funding and demonstrates ongoing confidence from its financial partners. The amendment also includes key structural changes: Bank of America (BofA) has been added as a new participant, while Credit Agricole and U.S. Bank have been removed. Furthermore, the facility will transition from LIBOR-based interest rate benchmarks to the Secured Overnight Financing Rate (SOFR), reflecting industry-wide shifts in benchmark rates. These adjustments aim to modernize the facility and ensure its continued effectiveness in managing the company's working capital needs.
CARDINAL HEALTH INC 8-K Report, Regulation FD Disclosure (Sep 13, 2022)
Cardinal Health Inc. (CAH) issued a Form 8-K on September 13, 2022, to update its financial guidance for the Medical segment's profit in the first quarter of fiscal year 2023. The company now expects a Medical segment loss ranging from $55 million to $25 million, a downward revision from its prior guidance of a $20 million loss to a $20 million profit. This adjustment is primarily driven by approximately $25 million in inventory charges related to the company's gloves portfolio, including charges for the sale of certain disposable gloves utilized in non-healthcare industries, stemming from ongoing simplification efforts. Despite the revised Medical segment outlook, Cardinal Health reaffirmed its full fiscal year 2023 non-GAAP diluted earnings per share guidance of $5.05 to $5.40. The company also noted that it will present this update at the Morgan Stanley 20th Annual Global Healthcare Conference on the same day, September 13, 2022. Investors should note the company's caution regarding forward-looking statements and the potential impact of various risks, including inflationary pressures, supply chain constraints, and competitive dynamics, on future results.
CARDINAL HEALTH INC 8-K Report, Executive Changes (Sep 8, 2022)
Cardinal Health Inc. (CAH) announced a significant leadership change within its Pharmaceutical Segment through an 8-K filing on September 8, 2022. Victor L. Crawford will be stepping down as Chief Executive Officer of the Pharmaceutical Segment, effective September 19, 2022. While he will remain with the company until November 13, 2022, to facilitate a smooth transition, his departure is being treated as an involuntary termination without cause under the Company's Senior Executive Severance Plan. This change is accompanied by broader organizational adjustments within the Pharmaceutical Segment, as detailed in a press release furnished with the filing. Investors should monitor the company's communication for further details on the replacement and the strategic implications of these changes for the Pharmaceutical Segment's future performance and direction. The severance package for Mr. Crawford is contingent upon the execution of a release and adherence to restrictive covenants.
CARDINAL HEALTH INC 8-K Report, Material Agreement (Sep 6, 2022)
Cardinal Health, Inc. (CAH) announced a significant governance development with the entry into a Cooperation Agreement with activist investor Elliott Associates, L.P. This agreement involves the immediate appointment of four new independent directors to the Board, including Elliott's Global Head of Engagement, Steven K. Barg, who will also serve on a newly formed Business Review Committee alongside the Company's CEO. This committee will advise the full Board on matters related to the agreement. Furthermore, two existing directors, Dean A. Scarborough and John H. Weiland, will not stand for re-election at the upcoming 2022 Annual Meeting, resulting in a reduced Board size. The company emphasized that these departures are not due to disagreements. The Cooperation Agreement outlines specific terms, including standstill provisions for Elliott and a commitment to nominate the new directors at the next annual meeting, subject to certain conditions related to Elliott's ownership stake. This move signals a collaborative approach to enhancing shareholder value and strengthening board oversight.
CARDINAL HEALTH INC 8-K Report, Executive Changes (Aug 11, 2022)
Cardinal Health, Inc. (CAH) announced significant leadership changes via an 8-K filing on August 11, 2022, with an event date of August 6, 2022. The most impactful news for investors is the appointment of Jason M. Hollar as the new Chief Executive Officer (CEO), effective September 1, 2022. Mr. Hollar, previously the company's CFO, will succeed Michael C. Kaufmann, who is departing the company. This transition signifies a change in leadership direction, and investors will be keen to understand Mr. Hollar's strategic vision for Cardinal Health. In addition to the CEO transition, the company has appointed Patricia M. English as Interim Chief Financial Officer (CFO) and Mary C. Scherer as Senior Vice President and Chief Accounting Officer, both effective September 1, 2022. The filing also outlines the compensation packages for Mr. Hollar and Ms. English as they assume their new roles, including base salary, bonus targets, long-term incentives, and retention awards. Investors should pay attention to the details of these compensation arrangements as they reflect the company's investment in its new leadership team.